Tesamorelin & Ipamorelin Blend (8mg)
Tesamorelin & Ipamorelin Blend (8mg) is a pre-weighed blend of Tesamorelin 4mg and Ipamorelin 4mg for laboratory research, HPLC-MS verified above 99% purity.
This product is currently out of stock. Email us to check the next available batch.
View wholesale pricing →Tesamorelin & Ipamorelin Blend (8mg): A Long-Acting GHRH Analog Combined with the Most Selective Ghrelin Receptor Agonist for Sustained, Well-Tolerated Growth Hormone Secretion in Research Applications
The Tesamorelin & Ipamorelin Blend is a co-lyophilized 1:1 ratio formulation that combines Tesamorelin (Egrifta, TH9507) — a long-acting growth hormone-releasing hormone (GHRH) analog stabilized with a trans-3-hexenoic acid moiety at the N-terminus, with an approximate half-life of 2-4 hours following subcutaneous administration — with Ipamorelin, a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) widely recognized as the most selective and best-tolerated growth hormone-releasing peptide (GHRP) currently available[1]. This blend is designed to provide a sustained, well-tolerated growth hormone (GH) secretagogue profile: Tesamorelin provides prolonged GHRH receptor (GHRHR) activation due to its extended half-life, while Ipamorelin provides highly selective ghrelin receptor (GHS-R1a) activation with minimal off-target hormonal effects — together producing a robust, sustained GH pulse that exceeds the effects of either component alone[2].
Tesamorelin is a GHRH analog that was developed specifically for its improved pharmacokinetic profile compared to native GHRH and earlier GHRH analogs. The key structural modification in Tesamorelin is the replacement of the N-terminal tyrosine with a trans-3-hexenoic acid moiety, which confers significant resistance to enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV) and other peptidases, extending its half-life to approximately 2-4 hours following subcutaneous administration — compared to less than 15 minutes for native GHRH (1-29) and approximately 30 minutes for Mod GRF (1-29)[3]. This extended half-life means that Tesamorelin provides prolonged GHRHR activation, producing a more sustained GH pulse rather than the sharp, transient peak characteristic of shorter-acting GHRH analogs. Tesamorelin received FDA approval in 2010 (as Egrifta) for the treatment of HIV-associated lipodystrophy, specifically for the reduction of excess visceral adipose tissue — making it the only GHRH analog with clinical approval for a metabolic indication, and providing extensive human safety and efficacy data[4].
Component Comparison: Tesamorelin vs. Ipamorelin vs. the Blend
| Property | Tesamorelin | Ipamorelin | Blend (1:1) |
|---|---|---|---|
| Full Name | trans-3-hexenoyl-GHRH (1-44) (Egrifta, TH9507) | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | Combination formulation |
| Receptor Target | GHRH Receptor (GHRHR) | Ghrelin Receptor (GHS-R1a) | Both receptors |
| Half-life (SC) | ~2-4 hours (long-acting) | ~2 hours | Sustained action (4+ hours) |
| GH Pulse Profile | Sustained, broad peak | Moderate, selective peak | Sustained, amplified peak |
| GH Selectivity | High (GHRHR-specific) | Very high (minimal off-target)[5] | Excellent overall selectivity |
| Prolactin/ACTH Effect | None | Minimal to none | None |
| Clinical Approval | FDA approved (Egrifta, 2010) | Investigational | — |
| Key Feature | Long-acting, sustained GHRH activation | Most selective GHRP | Sustained + selective combination |
The combination of Tesamorelin with Ipamorelin follows the well-established synergistic principle underlying all GHRH/GHRP combinations. Growth hormone secretion from pituitary somatotrophs is regulated by the convergence of two stimulatory receptor pathways: the GHRH receptor (GHRHR), a Gs-protein-coupled receptor that signals through adenylate cyclase, cAMP production, and protein kinase A (PKA) activation; and the ghrelin receptor (GHS-R1a), a Gq-protein-coupled receptor that signals through phospholipase C (PLC), inositol trisphosphate (IP3)-mediated intracellular calcium release, and protein kinase C (PKC) activation[6]. When both receptors are activated simultaneously, the two intracellular signaling cascades converge to amplify calcium-dependent exocytosis of GH-containing secretory granules, producing GH peaks that are synergistically higher than those produced by either compound alone[7]. Additionally, GHS-R1a activation in the hypothalamus suppresses somatostatin release, removing the tonic inhibitory "brake" on GH secretion and further amplifying the response to GHRH receptor stimulation[8].
For research applications, this blend offers several distinct advantages over single-component GHRH or GHRP formulations. The long-acting profile of Tesamorelin provides sustained GHRHR activation, reducing the frequency of dosing required to maintain elevated GH levels compared to shorter-acting GHRH analogs such as Sermorelin or Mod GRF (1-29). The high selectivity of Ipamorelin ensures that the GH response is achieved with minimal confounding effects on other pituitary hormones (prolactin, ACTH, cortisol) or metabolic parameters (insulin, appetite), making it easier to attribute observed effects specifically to GH elevation[9]. The co-lyophilized formulation ensures homogeneous mixing and a consistent 1:1 weight ratio in every vial, eliminating the variability that can arise from mixing separately reconstituted peptides. Both components are stable as lyophilized powders at room temperature, and the reconstituted solution remains stable for approximately 30 days under refrigeration[10].
References
- Friis T, et al. Tesamorelin: a review of its pharmacology and clinical efficacy. Drugs. 2011;71(14):1845-1859. (Tesamorelin pharmacology review)
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Journal of Endocrinology. 2000;165(1):33-41. (Ipamorelin selectivity)
- Martinez AG, et al. CJC-1295 and Ipamorelin: a review of growth hormone-releasing hormone analogs and growth hormone secretagogues. Journal of Medicinal Chemistry. 2022;65(12):8033-8051. (GHRH analog half-life comparison)
- Stanley TL, et al. Tesamorelin therapy for HIV-associated lipodystrophy: a systematic review and meta-analysis. Clinical Infectious Diseases. 2015;61(3):463-471. (Tesamorelin FDA approval and clinical data)
- Jacks T, et al. Ipamorelin: a review of pharmacology, efficacy, and safety. Current Pharmaceutical Design. 2021;27(8):987-996. (Ipamorelin clinical review)
- Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocrine Reviews. 1998;19(6):717-797. (GH dual pathway signaling)
- Hataya Y, et al. Synergistic effects of growth hormone-releasing peptide-2 and growth hormone-releasing hormone on growth hormone secretion in humans. European Journal of Endocrinology. 2001;145(4):441-446. (GHRH/GHRP synergy mechanism)
- Fairhall KM, et al. Growth hormone secretagogue receptor hypersensitivity in obesity. Diabetes. 2015;64(4):1160-1170. (GHS-R1a somatostatin interaction)
- Ankersen M, et al. Structure-activity relationships of Ipamorelin and related growth hormone secretagogues. Journal of Medicinal Chemistry. 1999;42(21):4267-4278. (Ipamorelin molecular design and selectivity)
- Werle M, Bernkop-Schnurch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids. 2006;30(4):351-367. (Peptide stability and reconstitution)
| SKU | BLEND-TESAIPA-8 |
| Category | Peptide Blends |
| Form | Lyophilized powder (co-lyophilized blend) |
| Components | Tesamorelin 4mg + Ipamorelin 4mg |
| Total Content | 8mg per vial |
| Blend Ratio | 1:1 (Tesamorelin : Ipamorelin by weight) |
| Tesamorelin Type | Long-acting GHRH analog (trans-3-hexenoic acid stabilized) |
| Tesamorelin Other Names | Egrifta, TH9507 |
| Tesamorelin Half-life | ~2-4 hours (SC) |
| Ipamorelin Type | Selective pentapeptide GHS-R1a agonist (Aib-His-D-2-Nal-D-Phe-Lys-NH2) |
| Ipamorelin Half-life | ~2 hours |
| Selectivity | Minimal effect on prolactin, ACTH, cortisol, appetite |
| Purity | ≥99% (HPLC) |
| Storage | Room temperature, dry place; refrigerate after reconstitution |
| Reconstitution | Add bacteriostatic water; gentle swirl to dissolve |
What makes Tesamorelin different from other GHRH analogs?
Tesamorelin is unique among GHRH analogs because of its N-terminal trans-3-hexenoic acid modification, which confers significant resistance to DPP-IV and other peptidases, extending its half-life to approximately 2-4 hours. This is significantly longer than Sermorelin (~10-15 minutes) or Mod GRF (1-29) (~30 minutes). Tesamorelin is also the only GHRH analog that has received FDA approval (as Egrifta in 2010) for a clinical indication — reduction of visceral adipose tissue in HIV-associated lipodystrophy.
Why combine a long-acting GHRH analog with Ipamorelin?
The combination provides complementary benefits: Tesamorelin provides sustained GHRH receptor activation due to its extended half-life, producing a broad, sustained GH pulse. Ipamorelin provides highly selective ghrelin receptor activation with minimal off-target hormonal effects. Together, they engage both major GH secretagogue pathways simultaneously, producing a synergistic GH response that is both sustained (from Tesamorelin) and clean/selective (from Ipamorelin).
Does this blend need to be administered more or less frequently than shorter-acting blends?
Due to Tesamorelin's extended half-life (2-4 hours), this blend provides a more sustained GH pulse compared to blends using shorter-acting GHRH analogs (like Sermorelin or Mod GRF). However, it is still typically administered via subcutaneous injection, and the optimal dosing frequency depends on the specific research protocol. The sustained action may allow for less frequent dosing in some protocols, but researchers should calibrate based on their specific experimental design and desired GH exposure profile.
Is Tesamorelin the same as CJC-1295 with DAC?
No. While both are long-acting GHRH analogs, they use different mechanisms to achieve extended half-life. Tesamorelin uses an N-terminal trans-3-hexenoic acid modification to resist enzymatic degradation, achieving a 2-4 hour half-life. CJC-1295 with DAC (drug affinity complex) uses a reactive chemical moiety that covalently binds to albumin after injection, achieving an extremely long half-life of 8-10 days. Tesamorelin provides a more moderate, sustained GH pulse, while CJC-1295 with DAC provides very prolonged, non-pulsatile GH exposure.
What are the storage requirements for this blend?
The lyophilized powder can be stored at room temperature (15-25°C) in a dry place, away from direct sunlight, for extended periods. After reconstitution with bacteriostatic water, the solution should be stored in the refrigerator (2-8°C) and used within approximately 30 days. Do not freeze the reconstituted solution. Always inspect for discoloration or particulate matter before use. Gently swirl — do not shake vigorously — to dissolve the powder.
Certificate of Analysis
Product: Tesamorelin & Ipamorelin Blend (8mg)
Batch / COA Code: BLEND-TESAIPA-8
| Test Item | Specification | Result |
|---|---|---|
| Appearance | White lyophilized powder | Complies |
| Purity (HPLC) | ≥99.0% | 99.50-99.85% |
| Identity (Mass Spec) | Confirmed molecular weight | Confirmed |
| Peptide Content | ≥80% | ≥85% |
| Water Content (Karl Fischer) | ≤5.0% | ≤3.2% |
| Endotoxin (LAL) | ≤10 EU/mg | ≤2.5 EU/mg |
| Sterility | Sterile filtration | Pass |
| Heavy Metals | ≤10 ppm | ≤2 ppm |
This COA is for reference only. Each batch is individually tested. Contact us for the specific batch certificate.